Elicera Therapeutics AB — Investor Relations & Filings

Elicera Therapeutics AB is a clinical-stage immuno-oncology company developing cell and gene therapies for cancer treatment. The company's portfolio is based on two main approaches: oncolytic viruses and Chimeric Antigen Receptor (CAR) T-cell therapies. A central component of its technology is the proprietary iTANK (Immuno-Oncology Targeting and Killing) platform. The iTANK platform is designed to enhance the efficacy of CAR T-cell therapies by arming them to activate a patient's own immune system, creating a broad, multi-targeted attack against cancer cells. This mechanism aims to address challenges such as tumor antigen heterogeneity, particularly in solid tumors. The company's pipeline includes several drug candidates in clinical development for indications including neuroendocrine tumors and B-cell lymphoma.